Sugi Predict

Sugi Predict / Compounds / SCHEMBL4183397

SCHEMBL4183397

SCHEMBL4183397

CC(C)(C)OC(=O)N1CCC(c2ccc(OC(F)(F)F)cc2)CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 5/20 0.61
▸ NAMPT P43490 1/20 0.56
▸ LIPE Q05469 1/20 0.54
▸ FAAH O00519 1/20 0.54
▸ EPHX2 P34913 2/20 0.50
▸ ALDH1A1 P00352 1/20 0.50
▸ P2RY14 Q15391 1/20 0.49
▸ KDM4E B2RXH2 1/20 0.49
▸ MAPT P10636 1/20 0.49
▸ THRB P10828 1/20 0.49
▸ KCNH2 Q12809 1/20 0.48
▸ SCN5A Q14524 1/20 0.48
▸ SCN9A Q15858 1/20 0.48
▸ DDB1 Q16531 1/20 0.47
▸ CRBN Q96SW2 1/20 0.47
▸ HTT P42858 1/20 0.47
▸ PTPN2 P17706 1/20 0.46
▸ PTPN1 P18031 1/20 0.46
▸ PTPN6 P29350 1/20 0.46
▸ PDE4B Q07343 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23211941 0.93 GPR119 (0.56) GPR119NAMPTLIPEFAAHEPHX2
SCHEMBL20757381 0.87 LIPE (0.56) GPR119NAMPTLIPEEPHX2KDM4E
SCHEMBL22944170 0.86 LIPE (0.54) GPR119LIPEEPHX2ALDH1A1MAPT
SCHEMBL25864470 0.85 GPR119 (0.52) GPR119NAMPTLIPEFAAHKDM4E
SCHEMBL7871974 0.85 ALDH1A1 (0.67) GPR119NAMPTFAAHALDH1A1KDM4E
SCHEMBL2951108 0.85 GPR119 (0.63) GPR119LIPEFAAHEPHX2ALDH1A1
SCHEMBL30482767 0.84 GPR119 (0.51) GPR119NAMPTLIPEEPHX2
SCHEMBL2297690 0.84 P2RY14 (0.64) GPR119NAMPTLIPEP2RY14KDM4E
SCHEMBL31615814 0.84 P2RY14 (0.59) GPR119NAMPTLIPEEPHX2ALDH1A1
SCHEMBL23411133 0.84 LIPE (0.57) GPR119NAMPTLIPEEPHX2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230014173-A1 Antibacterial Compounds JANSSEN SCIENCES IRELAND UC (IE) 2023-01-19 — — US disclosed
US-11180472-B2 Antibacterial compounds JANSSEN SCIENCES IRELAND UC (IE) 2021-11-23 — — US disclosed
EP-3027615-B1 ANTI-INFECTIVE COMPOUNDS PASTEUR INSTITUT KOREA (KR) 2021-07-21 — — EP disclosed
EP-3027615-B1 ANTI-INFECTIVE COMPOUNDS PASTEUR INSTITUT KOREA (KR) 2021-07-21 — — EP disclosed
US-20200239434-A1 ANTIBACTERIAL COMPOUNDS JANSSEN SCIENCES IRELAND UC (IE) 2020-07-30 — — US disclosed
US-20190330189-A1 ANTIBACTERIAL COMPOUNDS JANSSEN SCIENCES IRELAND UC (IE) 2019-10-31 — — US disclosed
US-10364232-B2 Antibacterial compounds JANSSEN SCIENCES IRELAND UC (IE) 2019-07-30 — — US disclosed
US-20180186768-A1 Antibacterial Compounds JANSSEN SCIENCES IRELAND UC (IE) 2018-07-05 — — US disclosed
US-20180155341-A1 Antibacterial Compounds JANSSEN SCIENCES IRELAND UC (IE) 2018-06-07 — — US disclosed
US-20160185774-A1 Anti-Infective Compounds INSTITUT PASTEUR KOREA (KR) 2016-06-30 — — US disclosed
EP-2573090-A1 (6,7-DIHYDRO-2-NITRO-5H-IMIDAZOL[2,1-B][1,3]OXAZIN-6-YL) AMIDE COMPOUNDS, PREPARATION METHODS AND USES THEREOF Shanghai Sun-Sail Pharmaceutical Science & Technology Co., Ltd (CN) 2013-03-27 — — EP disclosed
US-20090105305-A1 Therapeutic Agents - 550 ASTRAZENECA AB (SE) 2009-04-23 — — US disclosed
US-20090105305-A1 Therapeutic Agents - 550 ASTRAZENECA AB (SE) 2009-04-23 — — US disclosed
US-20090105305-A1 Therapeutic Agents - 550 ASTRAZENECA AB (SE) 2009-04-23 — — US disclosed
US-7427631-B2 especially as inhibitors of MMP12 ASTRAZENECA AB (SE) 2008-09-23 — — US disclosed
WO-2008075070-A1 SULFONAMIDE DERIVATIVES FOR THERAPEUTIC USE AS FATTY ACID SYNTHASE INHIBITORS ASTRAZENECA AB (SE) 2008-06-26 — — WO disclosed
EP-1370556-B1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2006-07-19 — — EP disclosed
EP-1676846-A2 Hydantoin derivatives as MMP inhibitors AstraZeneca AB (SE) 2006-07-05 — — EP disclosed
US-20040147573-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-07-29 — — US disclosed
US-20040127528-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-07-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11180472-B2 Antibacterial compounds FDPS, SQOR, NDUFS3 GPR119 4679/4885NAMPT 138/4885LIPE 3561/4885
US-20090105305-A1 Therapeutic Agents - 550 FABP4, GPR119, FASN GPR119 2/4885NAMPT 211/4885LIPE 80/4885
US-20190330189-A1 ANTIBACTERIAL COMPOUNDS FDPS, SQOR, NDUFS3 GPR119 4679/4885NAMPT 138/4885LIPE 3561/4885
US-10364232-B2 Antibacterial compounds FDPS, SQOR, NDUFS3 GPR119 4679/4885NAMPT 138/4885LIPE 3561/4885
US-20040127528-A1 Metalloproteinase inhibitors MMP9, MMP10, MMP3 GPR119 4215/4885NAMPT 609/4885LIPE 1752/4885
US-20160185774-A1 Anti-Infective Compounds RABGGTB, ELANE, SERPINB1 GPR119 4487/4885NAMPT 202/4885LIPE 2236/4885
US-20180186768-A1 Antibacterial Compounds FDPS, SQOR, NDUFS3 GPR119 4679/4885NAMPT 138/4885LIPE 3561/4885
US-20230014173-A1 Antibacterial Compounds FDPS, SQOR, NDUFS3 GPR119 4679/4885NAMPT 138/4885LIPE 3561/4885
US-20200239434-A1 ANTIBACTERIAL COMPOUNDS FDPS, SQOR, NDUFS3 GPR119 4679/4885NAMPT 138/4885LIPE 3561/4885
US-20180155341-A1 Antibacterial Compounds FDPS, SQOR, NDUFS3 GPR119 4679/4885NAMPT 138/4885LIPE 3561/4885
US-20040147573-A1 Metalloproteinase inhibitors MMP12, MMP7, MMP10 GPR119 2739/4885NAMPT 2518/4885LIPE 1310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.